Gissette Reyes-Soffer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gissette Reyes-Soffer has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
Rajasekhar Ramakrishnan
Center for Biomathematics, Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, USA
15 shared publicationsAnastasiya Matveyenko
Columbia University Vagelos College of Physicians and Surgeons, Department of Medicine, Division of Preventive Medicine and Nutrition, 630 West 168th street, P&S 8-503,New York, NY
12 shared publicationsTiffany Thomas
Columbia University Vagelos College of Physicians and Surgeons, Department of Medicine, Department Pathology & Cell Biology. 630 West 168 street, New York, NY
12 shared publicationsHenry N. Ginsberg
Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
9 shared publications- Henry N. Ginsberg
Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University
8 shared publications Stephen Holleran
Columbia University College of Physicians and Surgeons, New York, NY
8 shared publications
Latest Publications
- Open Access
Proteomic and Kinetic Analyses Reveal Discordant Apolipoprotein Turnover and Support a Revised Model of Human Lipoprotein(a) Metabolism
Lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease composed of apolipoprotein(a) [APO(a)] covalently linked to apolipoprotein B100 (APOB). Although plasma Lp(a) concentrations are largely genetically determined, the mechanisms governing Lp(a) metabolism after particle assembly remain poorly understood. We performed a cross sectional, observational study to define the Lp(a) proteome and determine the metabolic behavior of APO(a) and APOB within circulating Lp(a) particles using integrated proteomic, kinetic, and imaging approaches. Sixteen healthy adults underwent stable isotope tracer studies with ²H₃-L-leucine and ²H₅-glycerol. Lp(a) particles were isolated by APO(a)-specific immunoprecipitation for high-resolution liquid chromatography–mass spectrometry and kinetic analyses, and extracellular vesicles (EVs) were characterized by imaging flow cytometry and super-resolution microscopy. Proteomic analysis identified 92 proteins associated with immuno-isolated Lp(a), enriched in pathways related to immunity, coagulation, and atherogenesis. Lp(a)-APO(a) exhibited a mean fractional clearance rate of 0.04 pools/day, whereas Lp(a)-APOB cleared approximately sevenfold faster (0.25 pools/day), independent of plasma Lp(a) concentration or APO(a) isoform size. Both APO(a) and APOB were detected on circulating EVs, suggesting that EVs may contribute to post-secretory Lp(a) particle remodeling. These integrated human studies demonstrate marked discordance between APO(a) and APOB turnover within circulating Lp(a) particles, challenging the prevailing assumption that both apolipoproteins behave as a single metabolic unit after Lp(a) assembly and supporting a revised model of human Lp(a) metabolism.
Open AccessProteomic and Kinetic Analyses Reveal Discordant Apolipoprotein Turnover and Support a Revised Model of Human Lipoprotein(a) Metabolism
Lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease composed of apolipoprotein(a) [APO(a)] covalently linked to apolipoprotein B100 (APOB). Although plasma Lp(a) concentrations are largely genetically determined, the mechanisms governing Lp(a) metabolism after particle assembly remain poorly understood. We performed a cross sectional, observational study to define the Lp(a) proteome and determine the metabolic behavior of APO(a) and APOB within circulating Lp(a) particles using integrated proteomic, kinetic, and imaging approaches. Sixteen healthy adults underwent stable isotope tracer studies with ²H₃-L-leucine and ²H₅-glycerol. Lp(a) particles were isolated by APO(a)-specific immunoprecipitation for high-resolution liquid chromatography–mass spectrometry and kinetic analyses, and extracellular vesicles (EVs) were characterized by imaging flow cytometry and super-resolution microscopy. Proteomic analysis identified 92 proteins associated with immuno-isolated Lp(a), enriched in pathways related to immunity, coagulation, and atherogenesis. Lp(a)-APO(a) exhibited a mean fractional clearance rate of 0.04 pools/day, whereas Lp(a)-APOB cleared approximately sevenfold faster (0.25 pools/day), independent of plasma Lp(a) concentration or APO(a) isoform size. Both APO(a) and APOB were detected on circulating EVs, suggesting that EVs may contribute to post-secretory Lp(a) particle remodeling. These integrated human studies demonstrate marked discordance between APO(a) and APOB turnover within circulating Lp(a) particles, challenging the prevailing assumption that both apolipoproteins behave as a single metabolic unit after Lp(a) assembly and supporting a revised model of human Lp(a) metabolism.
- 7 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (13) , e043246
LPA Kringle IV Type‐2 Genetic Variants Are Associated With Apolipoprotein (a) Size, Hypertension, and Nonfasting Glucose Levels
Background: High plasma lipoprotein (a) (Lp[a]) levels, largely regulated by variation in the LPA gene, are a causal risk factor for atherosclerotic cardiovascular disease. LPA Kringle IV type 2 (KIV‐2) copy number (CN) inversely associates with Lp(a) levels, with Black and Hispanic individuals exhibiting higher Lp(a) levels than White individuals. These populations are underrepresented in genetic studies. We evaluated the ancestry‐specific LPA KIV‐2 variants and their associations with cardiometabolic and neurologic traits. Methods: Whole‐exome sequencing data from 3817 participants in the Washington Heights Inwood Columbia Aging Project were analyzed, including 886 non‐Hispanic White individuals (23%), 1811 Caribbean Hispanic individuals (47%), and 1120 Black individuals (29%). LPA KIV‐2 CN estimation and variant calling were performed using validated pipelines. Associations with clinical outcomes were evaluated using regression models adjusted for age, sex, and population substructure. Results: A total of 1421 variants were identified in the LPA KIV‐2 region, including 267 exonic variants, 35% shared across ancestry groups. LPA KIV‐2 CN correlated with 314 variants, 65.6% associated with lower KIV‐2 CN and higher Lp(a) levels. Three novel exonic variants (4785‐C/A, 727‐T/C, and 723‐A/G) positively associated with hypertension across ancestry groups. Variant 412‐C/T was associated to lower glucose levels, independently of KIV‐2 CN; 4785‐C/A was negatively associated with KIV‐CN ( P =2.3e‐159) and hypertension ( P =0.032); and in a small cohort, it was negatively associated with weighted isoform size ( P =1.5e‐4) and positively associated with Lp(a) levels ( P =0.012). Conclusions: Novel LPA KIV‐2 variants are enriched in individuals with low KIV‐2 CN and are associated with hypertension and glucose levels. These findings support further investigation into Lp(a)‐mediated mechanisms underlying atherosclerotic cardiovascular disease.
- 7 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (13) , e043246
LPA Kringle IV Type‐2 Genetic Variants Are Associated With Apolipoprotein (a) Size, Hypertension, and Nonfasting Glucose Levels
Background: High plasma lipoprotein (a) (Lp[a]) levels, largely regulated by variation in the LPA gene, are a causal risk factor for atherosclerotic cardiovascular disease. LPA Kringle IV type 2 (KIV‐2) copy number (CN) inversely associates with Lp(a) levels, with Black and Hispanic individuals exhibiting higher Lp(a) levels than White individuals. These populations are underrepresented in genetic studies. We evaluated the ancestry‐specific LPA KIV‐2 variants and their associations with cardiometabolic and neurologic traits. Methods: Whole‐exome sequencing data from 3817 participants in the Washington Heights Inwood Columbia Aging Project were analyzed, including 886 non‐Hispanic White individuals (23%), 1811 Caribbean Hispanic individuals (47%), and 1120 Black individuals (29%). LPA KIV‐2 CN estimation and variant calling were performed using validated pipelines. Associations with clinical outcomes were evaluated using regression models adjusted for age, sex, and population substructure. Results: A total of 1421 variants were identified in the LPA KIV‐2 region, including 267 exonic variants, 35% shared across ancestry groups. LPA KIV‐2 CN correlated with 314 variants, 65.6% associated with lower KIV‐2 CN and higher Lp(a) levels. Three novel exonic variants (4785‐C/A, 727‐T/C, and 723‐A/G) positively associated with hypertension across ancestry groups. Variant 412‐C/T was associated to lower glucose levels, independently of KIV‐2 CN; 4785‐C/A was negatively associated with KIV‐CN ( P =2.3e‐159) and hypertension ( P =0.032); and in a small cohort, it was negatively associated with weighted isoform size ( P =1.5e‐4) and positively associated with Lp(a) levels ( P =0.012). Conclusions: Novel LPA KIV‐2 variants are enriched in individuals with low KIV‐2 CN and are associated with hypertension and glucose levels. These findings support further investigation into Lp(a)‐mediated mechanisms underlying atherosclerotic cardiovascular disease.
- Open Access
Associations Between Plasma Lipoprotein(a) Levels and Circulating Monocyte Subsets Differ across Populations
Background: Lipoprotein(a) [Lp(a)] is a causal risk factor for cardiovascular disease (CVD), with plasma concentrations higher in Black individuals than in White individuals. Published findings support a model in which high Lp(a), in part through oxidized phospholipid (oxPL)-mediated signaling, promotes a pro-inflammatory monocyte phenotype that may contribute to arterial wall inflammation and the development of CVD. Here, we examined the relationship between Lp(a) concentrations and isoform size and the distribution of circulating monocyte populations in Black and White individuals using single-cell RNA sequencing (scRNA-seq) data. Methods: Using standardized assays, we measured plasma Lp(a) levels, isoform size, inflammatory markers, and oxidized phospholipids in stored plasma samples from our previously published cohort of 128 participants. After excluding smokers and individuals with type II diabetes, a total of 34 participants (20 Black participants, 14 White participants) were included in analyses. Participants were further stratified by plasma Lp(a) levels into normal Lp(a) [median 12.6 nmol/L, with 15 individuals (8 Black participants) and high Lp(a) (median 159 nmol/L, with 19 individuals (12 Black partcipants)]. Multivariable linear regression was used to assess the association between plasma Lp(a) levels, Lp(a)-oxPL, and the proportion of monocyte subsets. Across all participants, scRNA-seq data identified six classical monocyte subsets, one non-classical monocyte subset, one MHCII hi monocyte subset, and one interferon (IFN)-responsive monocyte subset. Results: The distribution of monocyte subsets was similar in individuals with normal versus high Lp(a) levels. Despite the small study cohort, self resported race modified the assocation between plasma Lp(a) levels and the proportion of non-classical monocytes ( P = 0.032), which was inversely associated in White participants ( P = 0.028), but not in Black partcipatns ( P = 0.470). OxPL bound to APO(a) showed a positive correlation with plasma Lp(a) levels (R 2 = 0.84; P = 3.3×10 −14 ), and non-classical monocytes ( P Whites = 0.027; P Blacks = 0.275; P Interaction = 0.014). Race also modified the association between plasma Lp(a) levels and the proportion of classical 2 monocytes ( P = 0.027). Conclusions: These results underscore the importance of self reported race when analysing studies on Lp(a), monocytes and, cardiovascular related monocyte immune functions.
Open AccessAssociations Between Plasma Lipoprotein(a) Levels and Circulating Monocyte Subsets Differ across Populations
Background: Lipoprotein(a) [Lp(a)] is a causal risk factor for cardiovascular disease (CVD), with plasma concentrations higher in Black individuals than in White individuals. Published findings support a model in which high Lp(a), in part through oxidized phospholipid (oxPL)-mediated signaling, promotes a pro-inflammatory monocyte phenotype that may contribute to arterial wall inflammation and the development of CVD. Here, we examined the relationship between Lp(a) concentrations and isoform size and the distribution of circulating monocyte populations in Black and White individuals using single-cell RNA sequencing (scRNA-seq) data. Methods: Using standardized assays, we measured plasma Lp(a) levels, isoform size, inflammatory markers, and oxidized phospholipids in stored plasma samples from our previously published cohort of 128 participants. After excluding smokers and individuals with type II diabetes, a total of 34 participants (20 Black participants, 14 White participants) were included in analyses. Participants were further stratified by plasma Lp(a) levels into normal Lp(a) [median 12.6 nmol/L, with 15 individuals (8 Black participants) and high Lp(a) (median 159 nmol/L, with 19 individuals (12 Black partcipants)]. Multivariable linear regression was used to assess the association between plasma Lp(a) levels, Lp(a)-oxPL, and the proportion of monocyte subsets. Across all participants, scRNA-seq data identified six classical monocyte subsets, one non-classical monocyte subset, one MHCII hi monocyte subset, and one interferon (IFN)-responsive monocyte subset. Results: The distribution of monocyte subsets was similar in individuals with normal versus high Lp(a) levels. Despite the small study cohort, self resported race modified the assocation between plasma Lp(a) levels and the proportion of non-classical monocytes ( P = 0.032), which was inversely associated in White participants ( P = 0.028), but not in Black partcipatns ( P = 0.470). OxPL bound to APO(a) showed a positive correlation with plasma Lp(a) levels (R 2 = 0.84; P = 3.3×10 −14 ), and non-classical monocytes ( P Whites = 0.027; P Blacks = 0.275; P Interaction = 0.014). Race also modified the association between plasma Lp(a) levels and the proportion of classical 2 monocytes ( P = 0.027). Conclusions: These results underscore the importance of self reported race when analysing studies on Lp(a), monocytes and, cardiovascular related monocyte immune functions.
- Open Access
- 27 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (7) , 2559
Comparative Proteomic Analysis of Lipoprotein(a): Method-Dependent Profiles and Disease Pathways
Background: Lipoprotein(a) [Lp(a)] is a genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD). Proteomic studies suggest that Lp(a)-associated proteins mediate inflammation, thrombosis, and vascular calcification, but methodological variability may influence proteome definition. Methods: Lp(a) was immunoprecipitated from human plasma using an apo(a)-specific monoclonal antibody and analyzed by mass spectrometry following either in-gel digestion or automated in-solution proteolysis. Proteins identified by ≥3 unique peptides and consistently detected across all samples by both methods were considered high confidence. Functional enrichment and interaction networks were assessed using STRING. Results: In-solution proteolysis identified 92 proteins and in-gel digestion identified 55 proteins, with 34 proteins shared between methods. These high-confidence proteins were enriched for pathways involved in lipoprotein remodeling, coagulation regulation, vesicle-mediated transport, lipid binding, and extracellular matrix organization, providing biological insight into mechanisms linking Lp(a) to inflammation, thrombosis, and calcification. Conclusions: Proteome composition of Lp(a) is method-dependent; however, a rigorously defined core proteome of 34 proteins was consistently identified across analytical approaches, highlighting biologically relevant pathways that may underlie Lp(a)-mediated ASCVD risk.
- 27 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (7) , 2559
Open AccessComparative Proteomic Analysis of Lipoprotein(a): Method-Dependent Profiles and Disease Pathways
Background: Lipoprotein(a) [Lp(a)] is a genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD). Proteomic studies suggest that Lp(a)-associated proteins mediate inflammation, thrombosis, and vascular calcification, but methodological variability may influence proteome definition. Methods: Lp(a) was immunoprecipitated from human plasma using an apo(a)-specific monoclonal antibody and analyzed by mass spectrometry following either in-gel digestion or automated in-solution proteolysis. Proteins identified by ≥3 unique peptides and consistently detected across all samples by both methods were considered high confidence. Functional enrichment and interaction networks were assessed using STRING. Results: In-solution proteolysis identified 92 proteins and in-gel digestion identified 55 proteins, with 34 proteins shared between methods. These high-confidence proteins were enriched for pathways involved in lipoprotein remodeling, coagulation regulation, vesicle-mediated transport, lipid binding, and extracellular matrix organization, providing biological insight into mechanisms linking Lp(a) to inflammation, thrombosis, and calcification. Conclusions: Proteome composition of Lp(a) is method-dependent; however, a rigorously defined core proteome of 34 proteins was consistently identified across analytical approaches, highlighting biologically relevant pathways that may underlie Lp(a)-mediated ASCVD risk.
- Open Access
- 30 May 2025
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 9 (1) , e139
Development of a peer and near-peer mentoring program to support early career research faculty: The ASPIRE! program
ASPIRE! (Accountability and Safe-space to Promote, Inspire, Recharge, and Empower) is a peer mentoring group and peer/near-peer mentoring program established in 2016 by a group of seven early career clinician and non-clinician, research faculty. All founding members participated in the TRANSFORM KL2 Program at Columbia University Irving Medical Center’s Irving Institute for Clinical and Translational Research. In this short communication, we describe the origins of this peer mentoring group established to support these seven early-career KL2 scholars. We also provide a summary of the development of an institution-wide peer mentoring program, created by the seven members of the initial peer mentoring group. We highlight how being at similar career stages, coming from different institutional departments, and sharing common academic goals in a safe space may have contributed to the success of the peer mentoring group. Our individual successes and experiences demonstrate that peer mentoring can be a powerful tool for enhancing the early-career academic experience.
- 30 May 2025
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 9 (1) , e139
Open AccessDevelopment of a peer and near-peer mentoring program to support early career research faculty: The ASPIRE! program
ASPIRE! (Accountability and Safe-space to Promote, Inspire, Recharge, and Empower) is a peer mentoring group and peer/near-peer mentoring program established in 2016 by a group of seven early career clinician and non-clinician, research faculty. All founding members participated in the TRANSFORM KL2 Program at Columbia University Irving Medical Center’s Irving Institute for Clinical and Translational Research. In this short communication, we describe the origins of this peer mentoring group established to support these seven early-career KL2 scholars. We also provide a summary of the development of an institution-wide peer mentoring program, created by the seven members of the initial peer mentoring group. We highlight how being at similar career stages, coming from different institutional departments, and sharing common academic goals in a safe space may have contributed to the success of the peer mentoring group. Our individual successes and experiences demonstrate that peer mentoring can be a powerful tool for enhancing the early-career academic experience.
- Open Access
- 1 January 2025
- Published by Science Exploration Press
- Vol. 1, 202508
Association of lipoprotein(a), oxidized phospholipids and apolipoprotein B100 in acute ischemic stroke cohort
Aims: Atherosclerosis, affecting the aorta, cervical, or intracranial arteries, is a common cause of stroke. Previous studies have shown a strong link between high Lp(a) levels and atherosclerotic stroke due to intracranial atherosclerotic disease, implicating Lp(a) in disease development and progression. The precise role of Lp(a) in stroke subtypes remains unclear, although smaller isoform sizes and oxidized phospholipids on Lp(a) are associated with the disease presence. To clarify Lp(a)’s connection with ischemic stroke subtypes, we evaluated various plasma biomarkers previously linked to Lp(a) and disease. Methods: We used stored plasma samples and data from 244 participants enrolled in an acute ischemic stroke registry at Columbia University Medical Center in New York. Plasma Lp(a) concentrations, apolipoprotein B100 (APOB), and oxidized phospholipids were measured via enzyme-linked immunosorbent assay. APO(a) isoform size was measured via gel electrophoresis. Stroke subtypes were classified based on etiologies using clinical and imaging data. Adjusted multivariate logistic regression models were built to assess associations between Lp(a)-related biomarkers and stroke subtype. Results: In participants with acute ischemic stroke, high Lp(a) concentrations, percentage of APOB in Lp(a), and OxPL-APO(a) concentrations were significantly associated with the presence of atherosclerotic stroke compared to those with non-atherosclerotic strokes [OR = 1.30 (p = 5.7e - 3), 1.29 (p = 6.9e - 3), 1.27 (p = 1.7e - 2), respectively]. In participants with atherosclerotic stroke, these changes were significantly associated with extracranial atherosclerotic stroke (ECAD), with an OR = 0.69, p = 4e - 2. Conclusion: In addition to Lp(a) concentrations, the percentage of APOB in Lp(a), and OxPL-APO(a) concentrations are positively associated with acute atherosclerotic ischemic stroke, specifically ECAD.
- 1 January 2025
- Published by Science Exploration Press
- Vol. 1, 202508
Open AccessAssociation of lipoprotein(a), oxidized phospholipids and apolipoprotein B100 in acute ischemic stroke cohort
Aims: Atherosclerosis, affecting the aorta, cervical, or intracranial arteries, is a common cause of stroke. Previous studies have shown a strong link between high Lp(a) levels and atherosclerotic stroke due to intracranial atherosclerotic disease, implicating Lp(a) in disease development and progression. The precise role of Lp(a) in stroke subtypes remains unclear, although smaller isoform sizes and oxidized phospholipids on Lp(a) are associated with the disease presence. To clarify Lp(a)’s connection with ischemic stroke subtypes, we evaluated various plasma biomarkers previously linked to Lp(a) and disease. Methods: We used stored plasma samples and data from 244 participants enrolled in an acute ischemic stroke registry at Columbia University Medical Center in New York. Plasma Lp(a) concentrations, apolipoprotein B100 (APOB), and oxidized phospholipids were measured via enzyme-linked immunosorbent assay. APO(a) isoform size was measured via gel electrophoresis. Stroke subtypes were classified based on etiologies using clinical and imaging data. Adjusted multivariate logistic regression models were built to assess associations between Lp(a)-related biomarkers and stroke subtype. Results: In participants with acute ischemic stroke, high Lp(a) concentrations, percentage of APOB in Lp(a), and OxPL-APO(a) concentrations were significantly associated with the presence of atherosclerotic stroke compared to those with non-atherosclerotic strokes [OR = 1.30 (p = 5.7e - 3), 1.29 (p = 6.9e - 3), 1.27 (p = 1.7e - 2), respectively]. In participants with atherosclerotic stroke, these changes were significantly associated with extracranial atherosclerotic stroke (ECAD), with an OR = 0.69, p = 4e - 2. Conclusion: In addition to Lp(a) concentrations, the percentage of APOB in Lp(a), and OxPL-APO(a) concentrations are positively associated with acute atherosclerotic ischemic stroke, specifically ECAD.
- Open Access
- 22 July 2024
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 18 (5) , e720-e728
Race/ethnicity and socioeconomic status affect the assessment of lipoprotein(a) levels in clinical practice
- 22 July 2024
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 18 (5) , e720-e728
Open AccessRace/ethnicity and socioeconomic status affect the assessment of lipoprotein(a) levels in clinical practice
- Open Access
Ancestry specific distribution of LPA Kringle IV-Type-2 genetic variants highlight associations to apo(a) copy number, glucose, and hypertension
Background: High Lp(a) levels contribute to atherosclerotic cardiovascular disease and are tightly regulated by the LPA gene. Lp(a) levels have an inverse correlation with LPA Kringle IV Type-2 (KIV-2) copy number (CN). Black (B) and Hispanic (H) individuals exhibit higher levels of Lp(a), and rates of CVD compared to non-Hispanic Whites (NHW). Therefore, we investigated genetic variations in the LPA KIV-2 region across three ancestries and their associations with metabolic risk factors. Methods: Using published pipelines, we analyzed a multi-ethnic whole exome dataset comprising 3,817 participants from the Washington Heights and Inwood Columbia Aging Project (WHICAP): 886 [NHW (23%), 1,811 Caribbean (C) H (47%), and 1,120 B individuals (29%). Rare and common variants (alternative allele carrier frequency, CF < 0.01 or > 0.99 and 0.01 < CF < 0.99, respectively) were identified and KIV-2 CN estimated. The associations of variants and CN with history of heart disease, hypertension (HTN), stroke, lipid levels and clinical diagnosis of Alzheimer’s disease (AD) was assessed. A small pilot provided in-silico validation of study findings. Results: We report 1421 variants in the LPA KIV-2 repeat region, comprising 267 exonic and 1154 intronic variants. 61.4% of the exonic variants have not been previously described. Three novel exonic variants significantly increase the risk of HTN across all ethnic groups: 4785-C/A (frequency = 78%, odds ratio [OR] = 1.45, p = 0.032), 727-T/C (frequency = 96%, OR = 2.11, p = 0.032), and 723-A/G (frequency = 96%, OR = 1.97, p = 0.038). Additionally, six intronic variants showed associations with HTN: 166-G/A, 387-G/C, 402-G/A, 4527-A/T, 4541-G/A, and 4653-A/T. One intronic variant, 412-C/T, was associated with decreased blood glucose levels (frequency = 72%, β = −14.52, p = 0.02). Three of the associations were not affected after adjusting for LPA KIV-2 CN: 412-C/T (β = −14.2, p = 0.03), 166-G/A (OR = 1.41, p = 0.05), and 387-G/C (OR = 1.40, p = 0.05). KIV CN itself was significantly associated with 314 variants and was negatively correlated with plasma total cholesterol levels. Conclusions: In three ancestry groups, we identify novel rare and common LPA KIV-2 region variants. We report new associations of variants with HTN and Glucose levels. These results underscore the genetic complexity of the LPA KIV-2 region in influencing cardiovascular and metabolic health, suggesting potential genetic regulation of pathways that can be studied for research and therapeutic interventions. Clinical Perspective: Lp(a) levels are mostly controlled by the LPA gene and are higher in Blacks and Hispanics. Novel LPA KIV-2 variants found in three ancestry groups, including data on Caribbean Hispanics, show strong positive associations to hypertension and negative associations to glucose levels. Further characterization of these variants and identifying links to disease can help precision medicine efforts to understand disease mechanisms in all populations.
Open AccessAncestry specific distribution of LPA Kringle IV-Type-2 genetic variants highlight associations to apo(a) copy number, glucose, and hypertension
Background: High Lp(a) levels contribute to atherosclerotic cardiovascular disease and are tightly regulated by the LPA gene. Lp(a) levels have an inverse correlation with LPA Kringle IV Type-2 (KIV-2) copy number (CN). Black (B) and Hispanic (H) individuals exhibit higher levels of Lp(a), and rates of CVD compared to non-Hispanic Whites (NHW). Therefore, we investigated genetic variations in the LPA KIV-2 region across three ancestries and their associations with metabolic risk factors. Methods: Using published pipelines, we analyzed a multi-ethnic whole exome dataset comprising 3,817 participants from the Washington Heights and Inwood Columbia Aging Project (WHICAP): 886 [NHW (23%), 1,811 Caribbean (C) H (47%), and 1,120 B individuals (29%). Rare and common variants (alternative allele carrier frequency, CF < 0.01 or > 0.99 and 0.01 < CF < 0.99, respectively) were identified and KIV-2 CN estimated. The associations of variants and CN with history of heart disease, hypertension (HTN), stroke, lipid levels and clinical diagnosis of Alzheimer’s disease (AD) was assessed. A small pilot provided in-silico validation of study findings. Results: We report 1421 variants in the LPA KIV-2 repeat region, comprising 267 exonic and 1154 intronic variants. 61.4% of the exonic variants have not been previously described. Three novel exonic variants significantly increase the risk of HTN across all ethnic groups: 4785-C/A (frequency = 78%, odds ratio [OR] = 1.45, p = 0.032), 727-T/C (frequency = 96%, OR = 2.11, p = 0.032), and 723-A/G (frequency = 96%, OR = 1.97, p = 0.038). Additionally, six intronic variants showed associations with HTN: 166-G/A, 387-G/C, 402-G/A, 4527-A/T, 4541-G/A, and 4653-A/T. One intronic variant, 412-C/T, was associated with decreased blood glucose levels (frequency = 72%, β = −14.52, p = 0.02). Three of the associations were not affected after adjusting for LPA KIV-2 CN: 412-C/T (β = −14.2, p = 0.03), 166-G/A (OR = 1.41, p = 0.05), and 387-G/C (OR = 1.40, p = 0.05). KIV CN itself was significantly associated with 314 variants and was negatively correlated with plasma total cholesterol levels. Conclusions: In three ancestry groups, we identify novel rare and common LPA KIV-2 region variants. We report new associations of variants with HTN and Glucose levels. These results underscore the genetic complexity of the LPA KIV-2 region in influencing cardiovascular and metabolic health, suggesting potential genetic regulation of pathways that can be studied for research and therapeutic interventions. Clinical Perspective: Lp(a) levels are mostly controlled by the LPA gene and are higher in Blacks and Hispanics. Novel LPA KIV-2 variants found in three ancestry groups, including data on Caribbean Hispanics, show strong positive associations to hypertension and negative associations to glucose levels. Further characterization of these variants and identifying links to disease can help precision medicine efforts to understand disease mechanisms in all populations.
- Open Access
- 13 June 2024
- Published by Elsevier in JVS-Vascular Science
- Vol. 5, 100211
Small apolipoprotein(a) isoforms may predict primary patency following peripheral arterial revascularization
- 13 June 2024
- Published by Elsevier in JVS-Vascular Science
- Vol. 5, 100211
Open AccessSmall apolipoprotein(a) isoforms may predict primary patency following peripheral arterial revascularization